CA3043373A1 - Pre-assembled, protected, chemically stable, chemoselective linkers - Google Patents

Pre-assembled, protected, chemically stable, chemoselective linkers Download PDF

Info

Publication number
CA3043373A1
CA3043373A1 CA3043373A CA3043373A CA3043373A1 CA 3043373 A1 CA3043373 A1 CA 3043373A1 CA 3043373 A CA3043373 A CA 3043373A CA 3043373 A CA3043373 A CA 3043373A CA 3043373 A1 CA3043373 A1 CA 3043373A1
Authority
CA
Canada
Prior art keywords
molecule
salt
alkyl
amino
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3043373A
Other languages
English (en)
French (fr)
Inventor
Patrick Walsh
David Smith
Gaurav Saini
Jae H. Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HealthTell Inc
Original Assignee
HealthTell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HealthTell Inc filed Critical HealthTell Inc
Publication of CA3043373A1 publication Critical patent/CA3043373A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0838—Compounds with one or more Si-O-Si sequences
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0838—Compounds with one or more Si-O-Si sequences
    • C07F7/087—Compounds of unknown structure containing a Si-O-Si sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rehabilitation Therapy (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
CA3043373A 2016-11-09 2017-11-08 Pre-assembled, protected, chemically stable, chemoselective linkers Abandoned CA3043373A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419861P 2016-11-09 2016-11-09
US62/419,861 2016-11-09
PCT/US2017/060721 WO2018089554A1 (en) 2016-11-09 2017-11-08 Pre-assembled, protected, chemically stable, chemoselective linkers

Publications (1)

Publication Number Publication Date
CA3043373A1 true CA3043373A1 (en) 2018-05-17

Family

ID=62109408

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043373A Abandoned CA3043373A1 (en) 2016-11-09 2017-11-08 Pre-assembled, protected, chemically stable, chemoselective linkers

Country Status (8)

Country Link
US (1) US12037311B2 (cg-RX-API-DMAC7.html)
EP (1) EP3538536A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019536770A (cg-RX-API-DMAC7.html)
KR (1) KR20190082871A (cg-RX-API-DMAC7.html)
CN (2) CN116514861A (cg-RX-API-DMAC7.html)
AU (1) AU2017359448A1 (cg-RX-API-DMAC7.html)
CA (1) CA3043373A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018089554A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223116A2 (en) 2016-06-20 2017-12-28 Healthtell Inc. Methods for differential diagnosis of autoimmune diseases
US11774446B2 (en) 2016-06-20 2023-10-03 Cowper Sciences Inc. Methods for diagnosis and treatment of autoimmune diseases
CA3043329A1 (en) 2016-11-09 2018-05-17 Healthtell Inc. Coatings with tunable amine density
KR20190082871A (ko) 2016-11-09 2019-07-10 헬스텔 인크. 선조립되고, 보호되고, 화학적으로 안정한, 화학선택적 링커
EP3538893A4 (en) 2016-11-11 2020-09-23 Healthtell Inc. PROCESSES FOR IDENTIFYING CANDIDATE BIOMARKERS

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6824866B1 (en) 1999-04-08 2004-11-30 Affymetrix, Inc. Porous silica substrates for polymer synthesis and assays
GB0001513D0 (en) 2000-01-25 2000-03-15 Univ Cranfield Rational design of mips using computational approach
CA2410887C (en) * 2000-06-02 2012-07-24 Bracco Research Usa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US20030219816A1 (en) 2001-07-02 2003-11-27 Keith Solomon Composite microarray slides
CN1125488C (zh) 2000-08-25 2003-10-22 中国科学院化学研究所 一种半导体封装用的液体环氧组合物及其用途
WO2002081649A2 (en) 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
US20030003223A1 (en) 2001-04-07 2003-01-02 The Regents Of The University Of California Methods and compositions for binding histidine-containing proteins to substrates
GB0121602D0 (en) 2001-09-06 2001-10-24 Randox Lab Ltd Molecular array
WO2003104814A2 (en) 2002-01-01 2003-12-18 Phynexus, Inc. Biomolecule open channel solid phase extraction systems and methods
US20060013971A1 (en) 2002-10-25 2006-01-19 Tienteh Chen Porous inkjet recording material
AU2003300815A1 (en) 2002-12-05 2004-06-30 Incyte Corporation Protein modification and maintenance molecules
KR100529600B1 (ko) 2003-01-23 2005-11-22 정만길 디옥소아테미시닌 유사체, 그의 제조방법 및 그를포함하는 항암제
JP4006523B2 (ja) 2003-04-10 2007-11-14 独立行政法人産業技術総合研究所 タンパク質アレイ及びその作製方法
WO2005050224A2 (en) 2003-11-13 2005-06-02 Epitome Biosystems Inc. Small molecule and peptide arrays and uses thereof
US7994118B2 (en) 2003-11-15 2011-08-09 Polyphor Ltd. Template fixed beta-hairpin loop mimetics and their use in phage display
WO2006090119A1 (en) 2005-02-23 2006-08-31 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
KR20070120112A (ko) * 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
US7507480B2 (en) 2005-05-31 2009-03-24 Brookhaven Science Associates, Llc Corrosion-resistant metal surfaces
KR100671659B1 (ko) 2005-12-21 2007-01-19 삼성에스디아이 주식회사 데이터 구동부 및 이를 이용한 유기 발광 표시장치와 그의구동방법
US7923054B2 (en) 2006-04-19 2011-04-12 Gore Enterprise Holdings, Inc. Functional porous substrates for attaching biomolecules
WO2007144685A1 (en) 2006-06-13 2007-12-21 Commissariat A L'energie Atomique Cd4 mimic peptides and their uses
US8148084B2 (en) 2006-06-22 2012-04-03 Dana-Farber Cancer Institute, Inc. Diagnosis of autoimmune disease
JP2008028123A (ja) 2006-07-20 2008-02-07 Sanyo Electric Co Ltd 半導体集積回路装置の製造方法
US20080254482A1 (en) 2006-11-22 2008-10-16 Invitrogen Corporation Autoimmune disease biomarkers
WO2008151146A2 (en) 2007-06-01 2008-12-11 Digitab, Inc. Peptide arrays and methods of use
WO2008156867A1 (en) 2007-06-21 2008-12-24 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for the diagnosis of autoimmune disease
JP2011001344A (ja) 2009-04-30 2011-01-06 L'oreal Sa アミノトリアルコキシシランまたはアミノトリアルケニルオキシシラン組成物を用いたヒトケラチン繊維の明色化および／または着色ならびに装置
US20120190574A1 (en) 2009-06-19 2012-07-26 The Arizona Board of Regents, A body Corporate of the State of Arizona for and on behalf of Arizona Compound Arrays for Sample Profiling
US8715685B2 (en) 2009-07-14 2014-05-06 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for HIV disease
WO2011041586A1 (en) 2009-09-30 2011-04-07 Virogenomics, Inc. Electromagnetic detection of analytes
US8698320B2 (en) 2009-12-07 2014-04-15 Henkel IP & Holding GmbH Curable resin compositions useful as underfill sealants for use with low-k dielectric-containing semiconductor devices
EP2539470B1 (en) 2010-02-24 2017-02-22 The Board of Trustees of The Leland Stanford Junior University Methods for autoimmune disease diagnosis, prognosis, and treatment
US20120237555A1 (en) 2011-03-16 2012-09-20 David Williams Surface coating for biomolecule immobilisation and minimisation of non-specific binding on surfaces for biomedical diagnostics
US9346892B2 (en) 2011-03-18 2016-05-24 Roche Nimble Gen, Inc. Methods for synthesis of an oligopeptide microarray
US9482666B2 (en) 2011-11-22 2016-11-01 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University High throughput selection of specific cell binding and lytic polypeptides
CA2864080C (en) 2012-02-07 2023-04-25 Vibrant Holdings, Llc Substrates, peptide arrays, and methods
US20130310265A1 (en) 2012-03-21 2013-11-21 North Carolina State University Methods of preparing cyclic peptides and uses thereof
ES2604012T3 (es) 2012-07-04 2017-03-02 F. Hoffmann-La Roche Ag Conjugados de antígeno-anticuerpo unidos covalentemente
WO2014036312A2 (en) 2012-08-29 2014-03-06 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State Of University Immunosignaturing: a path to early diagnosis and health monitoring
CN110187122A (zh) * 2012-09-05 2019-08-30 亚利桑那州评议委员会,亚利桑那州法人团体,代理和代表亚利桑那州立大学 发现治疗靶标的方法
WO2014062981A1 (en) 2012-10-17 2014-04-24 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University In situ chemical patterning
US9970932B2 (en) * 2013-03-15 2018-05-15 Arizona Board Of Regents On Behalf Of Arizona State University Non-covalent patterned chemical features and use thereof in MALDI-based quality control
KR102207770B1 (ko) 2013-08-05 2021-01-26 트위스트 바이오사이언스 코포레이션 드 노보 합성된 유전자 라이브러리
EP3169812A4 (en) 2014-07-18 2017-12-20 CDI Laboratories Inc. Methods and compositions to identify, quantify, and characterize target analytes and binding moieties
PT3177640T (pt) 2014-08-08 2020-08-31 Univ Leland Stanford Junior Agentes pd-1 de alta afinidade e métodos de utilização
AU2016251857B2 (en) 2015-04-23 2020-09-10 F. Hoffmann-La Roche Ag Method and composition for peptide cyclization and protease treatment
US10094825B2 (en) 2015-07-30 2018-10-09 The Florida International University Board Of Trustees Predictive biomarkers for detection of organ damage in autoimmune illnesses and other diseases
EP3436825A4 (en) 2016-04-01 2020-03-18 Healthtell Inc. NETWORK-BASED PEPTIDE BANKS FOR THE CHARACTERIZATION OF THERAPEUTIC ANTIBODIES
CA3043329A1 (en) 2016-11-09 2018-05-17 Healthtell Inc. Coatings with tunable amine density
KR20190082871A (ko) 2016-11-09 2019-07-10 헬스텔 인크. 선조립되고, 보호되고, 화학적으로 안정한, 화학선택적 링커
KR20200031613A (ko) 2017-06-19 2020-03-24 헬스텔 인크. 감별 진단을 위한 면역서명
EP3749676A4 (en) 2018-02-09 2021-12-22 Healthtell Inc. NETWORK BASED CYCLIC PEPTIDE BANKS
CN113677691A (zh) 2018-11-14 2021-11-19 库博科学公司 选择功能界面模拟物的方法及其组合物

Also Published As

Publication number Publication date
CN110072870A (zh) 2019-07-30
KR20190082871A (ko) 2019-07-10
US12037311B2 (en) 2024-07-16
AU2017359448A1 (en) 2019-05-30
WO2018089554A1 (en) 2018-05-17
JP2019536770A (ja) 2019-12-19
EP3538536A1 (en) 2019-09-18
US20190359566A1 (en) 2019-11-28
EP3538536A4 (en) 2020-05-13
CN116514861A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
US20220290005A1 (en) Coatings with tunable amine density
US12037311B2 (en) Pre-assembled, protected, chemically stable, chemoselective linkers
Borrebaeck et al. High-throughput proteomics using antibody microarrays: an update
JP6312225B2 (ja) タンパク質に対するペプチドバインダーの系統的探索、成熟化、および伸長
US20200326297A1 (en) Apparatuses and methods for detecting molecules and binding energy
JP2004530879A (ja) タンパク質マイクロアレイを構築する方法
Meng et al. The role of peptide microarrays in biomedical research
WO2020069661A1 (en) Serological biomarkers for early diagnosis of lung cancer
WO2018031247A1 (en) Apparatuses and methods for detecting molecules and binding energy
US20230096980A1 (en) Methods and systems for mask alignment in manufacturing process of arrays
KR20100127948A (ko) Ｓａｒｓ 코로나바이러스의 검출 및 억제용 펩타이드 화합물 및 그의 응용
JP2025524400A (ja) 抗リガンドを単離する方法
EP3602067B1 (en) Methods and kits for determining binding sites
US20100297779A1 (en) Biochip Self-Calibration Process
WO2021194978A1 (en) Pan-isotype immunoglobulin fingerprinting
Yamamoto et al. Microarray technologies for intracellular kinome analysis
Tapia et al. Exploring and profiling protein function with peptide arrays
Bertucci et al. Optical biosensors and applications to drug discovery and development in cancer research
Law et al. Protein binding assessment of immobilized nanobody using interferometric nanoporous platform
CN115561456A (zh) 体外定量b肝病毒大表面蛋白的套组以及用于处理肝病的生物指标组及单株抗体组
Santos et al. A Label-Free Nanobody-Conjugated Interferometric Protein Sensor
Cekaite et al. Monitoring B cell response to immunoselected phage-displayed peptides by microarrays

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230509